OncoMatch/Clinical Trials/NCT04930991
High Dose Omeprazole in Patients With Pancreatic Cancer
Is NCT04930991 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Omeprazole for exocrine pancreatic cancer.
Treatment: Omeprazole — The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Cardiac function
No clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stephenson Cancer Center · Oklahoma City, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify